Related references
Note: Only part of the references are listed.Clinical and histopathological predictors of outcome in malignant meningioma
Andrea D. Maier et al.
NEUROSURGICAL REVIEW (2020)
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis
Christian Mirian et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up
Adam Stenman et al.
ENDOCRINE PATHOLOGY (2019)
Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players
Xiaotian Yuan et al.
ONCOGENE (2019)
De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors
Matthieu Peyre et al.
NEURO-ONCOLOGY (2018)
TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma
Sabine Spiegl-Kreinecker et al.
NEURO-ONCOLOGY (2018)
High-grade meningiomas: biology and implications
Wenya Linda Bi et al.
NEUROSURGICAL FOCUS (2018)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2018)
Systematic analysis of telomere length and somatic alterations in 31 cancer types
Floris P. Barthel et al.
NATURE GENETICS (2017)
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas
Tareq A. Juratli et al.
ONCOTARGET (2017)
Genomic landscape of high-grade meningiomas
Wenya Linda Bi et al.
NPJ GENOMIC MEDICINE (2017)
Genomic profile of human meningioma cell lines
Yu Mei et al.
PLOS ONE (2017)
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Felix Sahm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Felix Sahm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States
Varun R. Kshettry et al.
NEURO-ONCOLOGY (2015)
High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression
Stephane Goutagny et al.
BRAIN PATHOLOGY (2014)
The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors
Tiantian Liu et al.
ENDOCRINE-RELATED CANCER (2014)
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
Jean Charles Nault et al.
NATURE COMMUNICATIONS (2013)
Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying NF2 Status
Stephane Goutagny et al.
CLINICAL CANCER RESEARCH (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Parallel Sequencing Used in Detection of Mosaic Mutations: Comparison With Four Diagnostic DNA Screening Techniques
Anna Rohlin et al.
HUMAN MUTATION (2009)
Alterations of the tumor suppressor genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in atypical and anaplastic meningiomas
J Boström et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
